{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Developmental+Defect&page=126",
    "query": {
      "condition": "Developmental Defect",
      "page": 126
    },
    "page_size": 10
  },
  "pagination": {
    "page": 126,
    "page_size": 10,
    "total_count": 10825,
    "total_pages": 1083,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Developmental+Defect&page=127&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Developmental+Defect&page=125&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-08T15:13:43.964Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06491927",
      "title": "Long Term Follow-up for RGX-202",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "No Intervention",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "REGENXBIO Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 66,
      "start_date": "2024-05-08",
      "completion_date": "2029-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-24",
      "last_synced_at": "2026-11-08T15:13:43.964Z",
      "location_count": 5,
      "location_summary": "Little Rock, Arkansas • Palo Alto, California • Chicago, Illinois + 2 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06491927"
    },
    {
      "nct_id": "NCT04091737",
      "title": "CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anemia, Sickle Cell"
      ],
      "interventions": [
        {
          "name": "Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "CSL Behring",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 1,
      "start_date": "2019-10-02",
      "completion_date": "2021-05-05",
      "has_results": false,
      "last_update_posted_date": "2021-06-18",
      "last_synced_at": "2026-11-08T15:13:43.964Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04091737"
    },
    {
      "nct_id": "NCT05377372",
      "title": "Early Life Exposures Among Children With Sickle Cell Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Adverse Childhood Experiences",
        "Breastfeeding"
      ],
      "interventions": [
        {
          "name": "Breastfeeding support group",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Observation",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2026-08-01",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-15",
      "last_synced_at": "2026-11-08T15:13:43.964Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05377372"
    },
    {
      "nct_id": "NCT03597399",
      "title": "A Patient Registry Study for Patients Treated With Voretigene Neparvovec in US",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy"
      ],
      "interventions": [
        {
          "name": "AAV2-hRPE65v2,voretigene neparvovec-rzyl",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Spark Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Months and older"
      },
      "enrollment_count": 87,
      "start_date": "2019-01-10",
      "completion_date": "2025-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-09-22",
      "last_synced_at": "2026-11-08T15:13:43.964Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Miami, Florida • Iowa City, Iowa + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03597399"
    },
    {
      "nct_id": "NCT02162732",
      "title": "Molecular-Guided Therapy for Childhood Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Neuroblastoma",
        "Medulloblastoma",
        "Glioma",
        "Ependymoma",
        "Choroid Plexus Neoplasms",
        "Craniopharyngioma",
        "Dysembryoplastic Neuroepithelial Tumor",
        "Meningioma",
        "Primitive Neuroectodermal Tumors (PNETs)",
        "Germ Cell Tumors",
        "Rhabdomyosarcoma",
        "Non-rhabdomyosarcoma",
        "Ewings Sarcoma",
        "Osteosarcoma",
        "Wilms Tumor",
        "Renal Cell Carcinoma",
        "Malignant Rhabdoid Tumor",
        "Clear Cell Sarcoma",
        "Liver Tumors"
      ],
      "interventions": [
        {
          "name": "Guided Therapy",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Giselle Sholler",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "13 Months to 21 Years"
      },
      "enrollment_count": 186,
      "start_date": "2014-07-08",
      "completion_date": "2024-01-18",
      "has_results": true,
      "last_update_posted_date": "2025-11-03",
      "last_synced_at": "2026-11-08T15:13:43.964Z",
      "location_count": 18,
      "location_summary": "Little Rock, Arkansas • San Diego, California • Hartford, Connecticut + 15 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02162732"
    },
    {
      "nct_id": "NCT01768663",
      "title": "A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "Lumacaftor",
          "type": "DRUG"
        },
        {
          "name": "Ivacaftor",
          "type": "DRUG"
        },
        {
          "name": "Ciprofloxacin",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        },
        {
          "name": "Rifampin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 80,
      "start_date": "2013-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-11-15",
      "last_synced_at": "2026-11-08T15:13:43.964Z",
      "location_count": 1,
      "location_summary": "Evansville, Indiana",
      "locations": [
        {
          "city": "Evansville",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01768663"
    },
    {
      "nct_id": "NCT01173016",
      "title": "Administration of IV Laronidase Post Bone Marrow Transplant in Hurler",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hurler Syndrome"
      ],
      "interventions": [
        {
          "name": "Laronidase",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "14 Years",
        "sex": "ALL",
        "summary": "Up to 14 Years"
      },
      "enrollment_count": 11,
      "start_date": "2012-05-29",
      "completion_date": "2016-03-04",
      "has_results": true,
      "last_update_posted_date": "2020-03-20",
      "last_synced_at": "2026-11-08T15:13:43.964Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01173016"
    },
    {
      "nct_id": "NCT01723553",
      "title": "Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Atypical Alzheimers Disease",
        "Logopenic Variant of Primary Progressive Aphasia (LPA)",
        "Posterior Cortical Atrophy (PCA)"
      ],
      "interventions": [
        {
          "name": "C-11 PiB",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2012-11",
      "completion_date": "2015-03",
      "has_results": false,
      "last_update_posted_date": "2015-12-21",
      "last_synced_at": "2026-11-08T15:13:43.964Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01723553"
    },
    {
      "nct_id": "NCT00515281",
      "title": "Inhaled Nitric Oxide and Neuroprotection in Premature Infants",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Prematurity",
        "Bronchopulmonary Dysplasia",
        "Intraventricular Hemorrhage",
        "Periventricular Leukomalacia"
      ],
      "interventions": [
        {
          "name": "inhaled nitric oxide",
          "type": "DRUG"
        },
        {
          "name": "oxygen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Hours",
        "maximum_age": "72 Hours",
        "sex": "ALL",
        "summary": "2 Hours to 72 Hours"
      },
      "enrollment_count": 273,
      "start_date": "2008-05",
      "completion_date": "2023-11-28",
      "has_results": true,
      "last_update_posted_date": "2024-10-17",
      "last_synced_at": "2026-11-08T15:13:43.964Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00515281"
    },
    {
      "nct_id": "NCT04639336",
      "title": "Cognitive and Neurological Pathologies in Pompe Disease",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pompe Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "0 Years to 18 Years"
      },
      "enrollment_count": 45,
      "start_date": "2016-08-03",
      "completion_date": "2029-03",
      "has_results": false,
      "last_update_posted_date": "2026-03-04",
      "last_synced_at": "2026-11-08T15:13:43.964Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04639336"
    }
  ]
}